The global market for Solid Tumors Drugs was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.

Solid tumors are an abnormal mass of tissue that do not contain cysts or liquid areas. These may be malignant (cancerous) or benign (not cancerous). They affect bones, organs, and muscles. Based on the type of the cells, solid tumors can be carcinomas, sarcomas, and lymphomas.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Solid Tumors Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Solid Tumors Drugs.

The Solid Tumors Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Pcs) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Solid Tumors Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Solid Tumors Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Solid Tumors Drugs Market Report

Report Metric	Details
Report Name	Solid Tumors Drugs Market
CAGR	5%
Segment by Type	Small Molecules Biologics
Segment by Application	Hospitals Clinics Academic and Research Institutes Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, BMS, Eli Lilly, GSK, Merck, Sanofi, AbbVie, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Boston Biomedical, Daiichi Sankyo
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Solid Tumors Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Solid Tumors Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Solid Tumors Drugs Market report?

Ans: The main players in the Solid Tumors Drugs Market are Hoffmann-La Roche, Novartis, Celgene, Johnson & Johnson, Pfizer, BMS, Eli Lilly, GSK, Merck, Sanofi, AbbVie, AstraZeneca, Bayer, Biogen, Boehringer Ingelheim, Boston Biomedical, Daiichi Sankyo

What are the Application segmentation covered in the Solid Tumors Drugs Market report?

Ans: The Applications covered in the Solid Tumors Drugs Market report are Hospitals, Clinics, Academic and Research Institutes, Others

What are the Type segmentation covered in the Solid Tumors Drugs Market report?

Ans: The Types covered in the Solid Tumors Drugs Market report are Small Molecules, Biologics

1 Solid Tumors Drugs Market Overview

1.1 Product Definition

1.2 Solid Tumors Drugs by Type

1.2.1 Global Solid Tumors Drugs Market Value Comparison by Type (2024 VS 2031)

1.2.2 Small Molecules

1.2.3 Biologics

1.3 Solid Tumors Drugs by Application

1.3.1 Global Solid Tumors Drugs Market Value by Application (2024 VS 2031)

1.3.2 Hospitals

1.3.3 Clinics

1.3.4 Academic and Research Institutes

1.3.5 Others

1.4 Global Solid Tumors Drugs Market Size Estimates and Forecasts

1.4.1 Global Solid Tumors Drugs Revenue 2020-2031

1.4.2 Global Solid Tumors Drugs Sales 2020-2031

1.4.3 Global Solid Tumors Drugs Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Solid Tumors Drugs Market Competition by Manufacturers

2.1 Global Solid Tumors Drugs Sales Market Share by Manufacturers (2020-2025)

2.2 Global Solid Tumors Drugs Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Solid Tumors Drugs Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Solid Tumors Drugs, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Solid Tumors Drugs, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Solid Tumors Drugs, Product Type & Application

2.7 Global Key Manufacturers of Solid Tumors Drugs, Date of Enter into This Industry

2.8 Global Solid Tumors Drugs Market Competitive Situation and Trends

2.8.1 Global Solid Tumors Drugs Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Solid Tumors Drugs Players Market Share by Revenue

2.8.3 Global Solid Tumors Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Solid Tumors Drugs Market Scenario by Region

3.1 Global Solid Tumors Drugs Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Solid Tumors Drugs Sales by Region: 2020-2031

3.2.1 Global Solid Tumors Drugs Sales by Region: 2020-2025

3.2.2 Global Solid Tumors Drugs Sales by Region: 2026-2031

3.3 Global Solid Tumors Drugs Revenue by Region: 2020-2031

3.3.1 Global Solid Tumors Drugs Revenue by Region: 2020-2025

3.3.2 Global Solid Tumors Drugs Revenue by Region: 2026-2031

3.4 North America Solid Tumors Drugs Market Facts & Figures by Country

3.4.1 North America Solid Tumors Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Solid Tumors Drugs Sales by Country (2020-2031)

3.4.3 North America Solid Tumors Drugs Revenue by Country (2020-2031)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Solid Tumors Drugs Market Facts & Figures by Country

3.5.1 Europe Solid Tumors Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Solid Tumors Drugs Sales by Country (2020-2031)

3.5.3 Europe Solid Tumors Drugs Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Solid Tumors Drugs Market Facts & Figures by Region

3.6.1 Asia Pacific Solid Tumors Drugs Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Solid Tumors Drugs Sales by Region (2020-2031)

3.6.3 Asia Pacific Solid Tumors Drugs Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Solid Tumors Drugs Market Facts & Figures by Country

3.7.1 Latin America Solid Tumors Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Solid Tumors Drugs Sales by Country (2020-2031)

3.7.3 Latin America Solid Tumors Drugs Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Solid Tumors Drugs Market Facts & Figures by Country

3.8.1 Middle East and Africa Solid Tumors Drugs Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Solid Tumors Drugs Sales by Country (2020-2031)

3.8.3 Middle East and Africa Solid Tumors Drugs Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4 Segment by Type

4.1 Global Solid Tumors Drugs Sales by Type (2020-2031)

4.1.1 Global Solid Tumors Drugs Sales by Type (2020-2025)

4.1.2 Global Solid Tumors Drugs Sales by Type (2026-2031)

4.1.3 Global Solid Tumors Drugs Sales Market Share by Type (2020-2031)

4.2 Global Solid Tumors Drugs Revenue by Type (2020-2031)

4.2.1 Global Solid Tumors Drugs Revenue by Type (2020-2025)

4.2.2 Global Solid Tumors Drugs Revenue by Type (2026-2031)

4.2.3 Global Solid Tumors Drugs Revenue Market Share by Type (2020-2031)

4.3 Global Solid Tumors Drugs Price by Type (2020-2031)

5 Segment by Application

5.1 Global Solid Tumors Drugs Sales by Application (2020-2031)

5.1.1 Global Solid Tumors Drugs Sales by Application (2020-2025)

5.1.2 Global Solid Tumors Drugs Sales by Application (2026-2031)

5.1.3 Global Solid Tumors Drugs Sales Market Share by Application (2020-2031)

5.2 Global Solid Tumors Drugs Revenue by Application (2020-2031)

5.2.1 Global Solid Tumors Drugs Revenue by Application (2020-2025)

5.2.2 Global Solid Tumors Drugs Revenue by Application (2026-2031)

5.2.3 Global Solid Tumors Drugs Revenue Market Share by Application (2020-2031)

5.3 Global Solid Tumors Drugs Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Hoffmann-La Roche

6.1.1 Hoffmann-La Roche Company Information

6.1.2 Hoffmann-La Roche Description and Business Overview

6.1.3 Hoffmann-La Roche Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Hoffmann-La Roche Solid Tumors Drugs Product Portfolio

6.1.5 Hoffmann-La Roche Recent Developments/Updates

6.2 Novartis

6.2.1 Novartis Company Information

6.2.2 Novartis Description and Business Overview

6.2.3 Novartis Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.2.4 Novartis Solid Tumors Drugs Product Portfolio

6.2.5 Novartis Recent Developments/Updates

6.3 Celgene

6.3.1 Celgene Company Information

6.3.2 Celgene Description and Business Overview

6.3.3 Celgene Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Celgene Solid Tumors Drugs Product Portfolio

6.3.5 Celgene Recent Developments/Updates

6.4 Johnson & Johnson

6.4.1 Johnson & Johnson Company Information

6.4.2 Johnson & Johnson Description and Business Overview

6.4.3 Johnson & Johnson Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Johnson & Johnson Solid Tumors Drugs Product Portfolio

6.4.5 Johnson & Johnson Recent Developments/Updates

6.5 Pfizer

6.5.1 Pfizer Company Information

6.5.2 Pfizer Description and Business Overview

6.5.3 Pfizer Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Pfizer Solid Tumors Drugs Product Portfolio

6.5.5 Pfizer Recent Developments/Updates

6.6 BMS

6.6.1 BMS Company Information

6.6.2 BMS Description and Business Overview

6.6.3 BMS Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.6.4 BMS Solid Tumors Drugs Product Portfolio

6.6.5 BMS Recent Developments/Updates

6.7 Eli Lilly

6.7.1 Eli Lilly Company Information

6.7.2 Eli Lilly Description and Business Overview

6.7.3 Eli Lilly Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.7.4 Eli Lilly Solid Tumors Drugs Product Portfolio

6.7.5 Eli Lilly Recent Developments/Updates

6.8 GSK

6.8.1 GSK Company Information

6.8.2 GSK Description and Business Overview

6.8.3 GSK Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.8.4 GSK Solid Tumors Drugs Product Portfolio

6.8.5 GSK Recent Developments/Updates

6.9 Merck

6.9.1 Merck Company Information

6.9.2 Merck Description and Business Overview

6.9.3 Merck Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Merck Solid Tumors Drugs Product Portfolio

6.9.5 Merck Recent Developments/Updates

6.10 Sanofi

6.10.1 Sanofi Company Information

6.10.2 Sanofi Description and Business Overview

6.10.3 Sanofi Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Sanofi Solid Tumors Drugs Product Portfolio

6.10.5 Sanofi Recent Developments/Updates

6.11 AbbVie

6.11.1 AbbVie Company Information

6.11.2 AbbVie Description and Business Overview

6.11.3 AbbVie Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.11.4 AbbVie Solid Tumors Drugs Product Portfolio

6.11.5 AbbVie Recent Developments/Updates

6.12 AstraZeneca

6.12.1 AstraZeneca Company Information

6.12.2 AstraZeneca Description and Business Overview

6.12.3 AstraZeneca Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.12.4 AstraZeneca Solid Tumors Drugs Product Portfolio

6.12.5 AstraZeneca Recent Developments/Updates

6.13 Bayer

6.13.1 Bayer Company Information

6.13.2 Bayer Description and Business Overview

6.13.3 Bayer Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.13.4 Bayer Solid Tumors Drugs Product Portfolio

6.13.5 Bayer Recent Developments/Updates

6.14 Biogen

6.14.1 Biogen Company Information

6.14.2 Biogen Description and Business Overview

6.14.3 Biogen Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.14.4 Biogen Solid Tumors Drugs Product Portfolio

6.14.5 Biogen Recent Developments/Updates

6.15 Boehringer Ingelheim

6.15.1 Boehringer Ingelheim Company Information

6.15.2 Boehringer Ingelheim Description and Business Overview

6.15.3 Boehringer Ingelheim Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.15.4 Boehringer Ingelheim Solid Tumors Drugs Product Portfolio

6.15.5 Boehringer Ingelheim Recent Developments/Updates

6.16 Boston Biomedical

6.16.1 Boston Biomedical Company Information

6.16.2 Boston Biomedical Description and Business Overview

6.16.3 Boston Biomedical Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.16.4 Boston Biomedical Solid Tumors Drugs Product Portfolio

6.16.5 Boston Biomedical Recent Developments/Updates

6.17 Daiichi Sankyo

6.17.1 Daiichi Sankyo Company Information

6.17.2 Daiichi Sankyo Description and Business Overview

6.17.3 Daiichi Sankyo Solid Tumors Drugs Sales, Revenue and Gross Margin (2020-2025)

6.17.4 Daiichi Sankyo Solid Tumors Drugs Product Portfolio

6.17.5 Daiichi Sankyo Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Solid Tumors Drugs Industry Chain Analysis

7.2 Solid Tumors Drugs Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Solid Tumors Drugs Production Mode & Process Analysis

7.4 Solid Tumors Drugs Sales and Marketing

7.4.1 Solid Tumors Drugs Sales Channels

7.4.2 Solid Tumors Drugs Distributors

7.5 Solid Tumors Drugs Customer Analysis

8 Solid Tumors Drugs Market Dynamics

8.1 Solid Tumors Drugs Industry Trends

8.2 Solid Tumors Drugs Market Drivers

8.3 Solid Tumors Drugs Market Challenges

8.4 Solid Tumors Drugs Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

List of Tables

Table 1. Global Solid Tumors Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Solid Tumors Drugs Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Solid Tumors Drugs Market Competitive Situation by Manufacturers in 2024

Table 4. Global Solid Tumors Drugs Sales (K Pcs) of Key Manufacturers (2020-2025)

Table 5. Global Solid Tumors Drugs Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Solid Tumors Drugs Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Solid Tumors Drugs Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Solid Tumors Drugs Average Price (USD/Pcs) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Solid Tumors Drugs, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Solid Tumors Drugs, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Solid Tumors Drugs, Product Type & Application

Table 12. Global Key Manufacturers of Solid Tumors Drugs, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Solid Tumors Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Solid Tumors Drugs as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Solid Tumors Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Solid Tumors Drugs Sales by Region (2020-2025) & (K Pcs)

Table 18. Global Solid Tumors Drugs Sales Market Share by Region (2020-2025)

Table 19. Global Solid Tumors Drugs Sales by Region (2026-2031) & (K Pcs)

Table 20. Global Solid Tumors Drugs Sales Market Share by Region (2026-2031)

Table 21. Global Solid Tumors Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Solid Tumors Drugs Revenue Market Share by Region (2020-2025)

Table 23. Global Solid Tumors Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Solid Tumors Drugs Revenue Market Share by Region (2026-2031)

Table 25. North America Solid Tumors Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Solid Tumors Drugs Sales by Country (2020-2025) & (K Pcs)

Table 27. North America Solid Tumors Drugs Sales by Country (2026-2031) & (K Pcs)

Table 28. North America Solid Tumors Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Solid Tumors Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Solid Tumors Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Solid Tumors Drugs Sales by Country (2020-2025) & (K Pcs)

Table 32. Europe Solid Tumors Drugs Sales by Country (2026-2031) & (K Pcs)

Table 33. Europe Solid Tumors Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Solid Tumors Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Solid Tumors Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Solid Tumors Drugs Sales by Region (2020-2025) & (K Pcs)

Table 37. Asia Pacific Solid Tumors Drugs Sales by Region (2026-2031) & (K Pcs)

Table 38. Asia Pacific Solid Tumors Drugs Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Solid Tumors Drugs Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Solid Tumors Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Solid Tumors Drugs Sales by Country (2020-2025) & (K Pcs)

Table 42. Latin America Solid Tumors Drugs Sales by Country (2026-2031) & (K Pcs)

Table 43. Latin America Solid Tumors Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Solid Tumors Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Solid Tumors Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Solid Tumors Drugs Sales by Country (2020-2025) & (K Pcs)

Table 47. Middle East and Africa Solid Tumors Drugs Sales by Country (2026-2031) & (K Pcs)

Table 48. Middle East and Africa Solid Tumors Drugs Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Solid Tumors Drugs Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Solid Tumors Drugs Sales (K Pcs) by Type (2020-2025)

Table 51. Global Solid Tumors Drugs Sales (K Pcs) by Type (2026-2031)

Table 52. Global Solid Tumors Drugs Sales Market Share by Type (2020-2025)

Table 53. Global Solid Tumors Drugs Sales Market Share by Type (2026-2031)

Table 54. Global Solid Tumors Drugs Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Solid Tumors Drugs Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Solid Tumors Drugs Revenue Market Share by Type (2020-2025)

Table 57. Global Solid Tumors Drugs Revenue Market Share by Type (2026-2031)

Table 58. Global Solid Tumors Drugs Price (USD/Pcs) by Type (2020-2025)

Table 59. Global Solid Tumors Drugs Price (USD/Pcs) by Type (2026-2031)

Table 60. Global Solid Tumors Drugs Sales (K Pcs) by Application (2020-2025)

Table 61. Global Solid Tumors Drugs Sales (K Pcs) by Application (2026-2031)

Table 62. Global Solid Tumors Drugs Sales Market Share by Application (2020-2025)

Table 63. Global Solid Tumors Drugs Sales Market Share by Application (2026-2031)

Table 64. Global Solid Tumors Drugs Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Solid Tumors Drugs Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Solid Tumors Drugs Revenue Market Share by Application (2020-2025)

Table 67. Global Solid Tumors Drugs Revenue Market Share by Application (2026-2031)

Table 68. Global Solid Tumors Drugs Price (USD/Pcs) by Application (2020-2025)

Table 69. Global Solid Tumors Drugs Price (USD/Pcs) by Application (2026-2031)

Table 70. Hoffmann-La Roche Company Information

Table 71. Hoffmann-La Roche Description and Business Overview

Table 72. Hoffmann-La Roche Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 73. Hoffmann-La Roche Solid Tumors Drugs Product

Table 74. Hoffmann-La Roche Recent Developments/Updates

Table 75. Novartis Company Information

Table 76. Novartis Description and Business Overview

Table 77. Novartis Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 78. Novartis Solid Tumors Drugs Product

Table 79. Novartis Recent Developments/Updates

Table 80. Celgene Company Information

Table 81. Celgene Description and Business Overview

Table 82. Celgene Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 83. Celgene Solid Tumors Drugs Product

Table 84. Celgene Recent Developments/Updates

Table 85. Johnson & Johnson Company Information

Table 86. Johnson & Johnson Description and Business Overview

Table 87. Johnson & Johnson Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 88. Johnson & Johnson Solid Tumors Drugs Product

Table 89. Johnson & Johnson Recent Developments/Updates

Table 90. Pfizer Company Information

Table 91. Pfizer Description and Business Overview

Table 92. Pfizer Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 93. Pfizer Solid Tumors Drugs Product

Table 94. Pfizer Recent Developments/Updates

Table 95. BMS Company Information

Table 96. BMS Description and Business Overview

Table 97. BMS Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 98. BMS Solid Tumors Drugs Product

Table 99. BMS Recent Developments/Updates

Table 100. Eli Lilly Company Information

Table 101. Eli Lilly Description and Business Overview

Table 102. Eli Lilly Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 103. Eli Lilly Solid Tumors Drugs Product

Table 104. Eli Lilly Recent Developments/Updates

Table 105. GSK Company Information

Table 106. GSK Description and Business Overview

Table 107. GSK Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 108. GSK Solid Tumors Drugs Product

Table 109. GSK Recent Developments/Updates

Table 110. Merck Company Information

Table 111. Merck Description and Business Overview

Table 112. Merck Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 113. Merck Solid Tumors Drugs Product

Table 114. Merck Recent Developments/Updates

Table 115. Sanofi Company Information

Table 116. Sanofi Description and Business Overview

Table 117. Sanofi Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 118. Sanofi Solid Tumors Drugs Product

Table 119. Sanofi Recent Developments/Updates

Table 120. AbbVie Company Information

Table 121. AbbVie Description and Business Overview

Table 122. AbbVie Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 123. AbbVie Solid Tumors Drugs Product

Table 124. AbbVie Recent Developments/Updates

Table 125. AstraZeneca Company Information

Table 126. AstraZeneca Description and Business Overview

Table 127. AstraZeneca Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 128. AstraZeneca Solid Tumors Drugs Product

Table 129. AstraZeneca Recent Developments/Updates

Table 130. Bayer Company Information

Table 131. Bayer Description and Business Overview

Table 132. Bayer Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 133. Bayer Solid Tumors Drugs Product

Table 134. Bayer Recent Developments/Updates

Table 135. Biogen Company Information

Table 136. Biogen Description and Business Overview

Table 137. Biogen Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 138. Biogen Solid Tumors Drugs Product

Table 139. Biogen Recent Developments/Updates

Table 140. Boehringer Ingelheim Company Information

Table 141. Boehringer Ingelheim Description and Business Overview

Table 142. Boehringer Ingelheim Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 143. Boehringer Ingelheim Solid Tumors Drugs Product

Table 144. Boehringer Ingelheim Recent Developments/Updates

Table 145. Boston Biomedical Company Information

Table 146. Boston Biomedical Description and Business Overview

Table 147. Boston Biomedical Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 148. Boston Biomedical Solid Tumors Drugs Product

Table 149. Boston Biomedical Recent Developments/Updates

Table 150. Daiichi Sankyo Company Information

Table 151. Daiichi Sankyo Description and Business Overview

Table 152. Daiichi Sankyo Solid Tumors Drugs Sales (K Pcs), Revenue (US$ Million), Price (USD/Pcs) and Gross Margin (2020-2025)

Table 153. Daiichi Sankyo Solid Tumors Drugs Product

Table 154. Daiichi Sankyo Recent Developments/Updates

Table 155. Key Raw Materials Lists

Table 156. Raw Materials Key Suppliers Lists

Table 157. Solid Tumors Drugs Distributors List

Table 158. Solid Tumors Drugs Customers List

Table 159. Solid Tumors Drugs Market Trends

Table 160. Solid Tumors Drugs Market Drivers

Table 161. Solid Tumors Drugs Market Challenges

Table 162. Solid Tumors Drugs Market Restraints

Table 163. Research Programs/Design for This Report

Table 164. Key Data Information from Secondary Sources

Table 165. Key Data Information from Primary Sources

Table 166. Authors List of This Report

List of Figures

Figure 1. Product Picture of Solid Tumors Drugs

Figure 2. Global Solid Tumors Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Solid Tumors Drugs Market Share by Type: 2024 & 2031

Figure 4. Small Molecules Product Picture

Figure 5. Biologics Product Picture

Figure 6. Global Solid Tumors Drugs Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Solid Tumors Drugs Market Share by Application: 2024 & 2031

Figure 8. Hospitals

Figure 9. Clinics

Figure 10. Academic and Research Institutes

Figure 11. Others

Figure 12. Global Solid Tumors Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 13. Global Solid Tumors Drugs Market Size (2020-2031) & (US$ Million)

Figure 14. Global Solid Tumors Drugs Sales (2020-2031) & (K Pcs)

Figure 15. Global Solid Tumors Drugs Average Price (USD/Pcs) & (2020-2031)

Figure 16. Solid Tumors Drugs Report Years Considered

Figure 17. Solid Tumors Drugs Sales Share by Manufacturers in 2024

Figure 18. Global Solid Tumors Drugs Revenue Share by Manufacturers in 2024

Figure 19. Global 5 and 10 Largest Solid Tumors Drugs Players: Market Share by Revenue in Solid Tumors Drugs in 2024

Figure 20. Solid Tumors Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 21. Global Solid Tumors Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 22. North America Solid Tumors Drugs Sales Market Share by Country (2020-2031)

Figure 23. North America Solid Tumors Drugs Revenue Market Share by Country (2020-2031)

Figure 24. U.S. Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Canada Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 26. Europe Solid Tumors Drugs Sales Market Share by Country (2020-2031)

Figure 27. Europe Solid Tumors Drugs Revenue Market Share by Country (2020-2031)

Figure 28. Germany Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. France Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. U.K. Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Italy Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Russia Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 33. Asia Pacific Solid Tumors Drugs Sales Market Share by Region (2020-2031)

Figure 34. Asia Pacific Solid Tumors Drugs Revenue Market Share by Region (2020-2031)

Figure 35. China Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. Japan Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. South Korea Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. India Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. Australia Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Taiwan Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Indonesia Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Thailand Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Malaysia Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 44. Philippines Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 45. Latin America Solid Tumors Drugs Sales Market Share by Country (2020-2031)

Figure 46. Latin America Solid Tumors Drugs Revenue Market Share by Country (2020-2031)

Figure 47. Mexico Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Brazil Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 49. Argentina Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 50. Middle East and Africa Solid Tumors Drugs Sales Market Share by Country (2020-2031)

Figure 51. Middle East and Africa Solid Tumors Drugs Revenue Market Share by Country (2020-2031)

Figure 52. Turkey Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Saudi Arabia Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 54. U.A.E Solid Tumors Drugs Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 55. Global Sales Market Share of Solid Tumors Drugs by Type (2020-2031)

Figure 56. Global Revenue Market Share of Solid Tumors Drugs by Type (2020-2031)

Figure 57. Global Solid Tumors Drugs Price (USD/Pcs) by Type (2020-2031)

Figure 58. Global Sales Market Share of Solid Tumors Drugs by Application (2020-2031)

Figure 59. Global Revenue Market Share of Solid Tumors Drugs by Application (2020-2031)

Figure 60. Global Solid Tumors Drugs Price (USD/Pcs) by Application (2020-2031)

Figure 61. Solid Tumors Drugs Value Chain

Figure 62. Channels of Distribution (Direct Vs Distribution)

Figure 63. Bottom-up and Top-down Approaches for This Report

Figure 64. Data Triangulation

Figure 65. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions